Express News | Bide Pharma: The company's Director, Vice General Manager, and core technical staff member Wang Chao has resigned.

BreakingsDec 13 17:50

A-share fluctuations | Bide Pharmaceutical rises over 7% as the actual controller proposes to buy back shares.

On November 26th, BiDe Pharmaceuticals (688073.SH) surged over 7% to 46.12 yuan, with a total market value of 4.2 billion yuan. The company announced after hours yesterday that the actual controller, chairman, and general manager Dai Lan proposed the company to repurchase shares, with the purpose of using the repurchased shares for stock-based incentives, employee stock ownership plans, or for cancellation and reduction of the company's registered capital. The total amount of repurchase funds shall not be less than 50 million yuan and shall not exceed 0.1 billion yuan. In addition, Huachuang Securities recently stated that the company continues to strengthen its presence in overseas markets, with the operating performance steadily improving, and maintained a "recommended" rating. (Gelonghui)

Gelonghui FinanceNov 26 10:37

Bide Pharmaceutical (688073.SH): The actual controller, Dai Lan, proposed that the company repurchase shares again.

On November 25, Gelonghui announced that the board of directors of BiDe Pharmaceutical (688073.SH) received a letter from Ms. Dai Lan, the actual controller, chairman, and general manager of the company, on November 24, 2024, proposing the repurchase of the company's shares. Ms. Dai Lan proposed that the company repurchase some of the RMB ordinary shares (A shares) already issued by the company through the Shanghai Stock Exchange trading system using centralized bidding trading method, using the repurchased shares for stock-based incentives, employee stock ownership plans, or for the cancellation and reduction of the company's registered capital. The total amount of the repurchase funds shall not be less than RMB 50 million.

Gelonghui FinanceNov 25 16:50

Bede Pharmaceutical (688073) Third Quarter Report Review 2024: Overseas markets continue to exert strength, and the operation is steadily improving.

Subject: The company releases the third quarter report for 2024. In the first three quarters of 2024, the company's revenue was 0.811 billion yuan, a year-on-year increase of 0.79%, net income attributable to the mother was 0.084 billion yuan, a year-on-year decrease of 26.05%, and non-net income was 0.

Huachuang SecuritiesNov 12 00:00

Bide Pharmaceutical (688073): Profitability continues to improve with steady revenue growth.

Event: In the first three quarters of 2024, revenue reached 0.811 billion yuan (+0.79% year-on-year), net income attributable to parent company was 83.8539 million yuan (-26.05% year-on-year), non-net income attributable to parent company was 72.3904 million yuan.

财通证券Oct 25 19:51

Bide Pharmaceutical (688073): Structural adjustment, obvious elasticity, moving out of the low point of profitability.

Investment Highlights Performance: Revenue growth rate slowed down, profit growth rate rebounded in 2024Q1-3, achieving revenue of 0.811 billion yuan, yoy +0.79%; achieving net income attributable to parent company of 0.084 billion yuan, yoy -26.05%.

zheshang securitiesOct 25 00:00